Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.

Bone morphogenetic proteins (BMPs) are known to induce ectopic bone. However, it is largely unknown how BMP signaling in osteoblasts directly regulates endogenous bone. This study investigated the mechanism by which BMP signaling through the type IA receptor (BMPR1A) regulates endogenous bone mass using an inducible Cre-loxP system. When BMPR1A in osteoblasts was conditionally disrupted during embryonic bone development, bone mass surprisingly was increased with upregulation of canonical Wnt signaling. Although levels of bone formation markers were modestly reduced, levels of resorption markers representing osteoclastogenesis were severely reduced, resulting in a net increase in bone mass. The reduction of osteoclastogenesis was primarily caused by Bmpr1a-deficiency in osteoblasts, at least through the RANKL-OPG pathway. Sclerostin (Sost) expression was downregulated by about 90% and SOST protein was undetectable in osteoblasts and osteocytes, whereas the Wnt signaling was upregulated. Treatment of Bmpr1a-deficient calvariae with sclerostin repressed the Wnt signaling and restored normal bone morphology. By gain of Smad-dependent BMPR1A signaling in mice, Sost expression was upregulated and osteoclastogenesis was increased. Finally, the Bmpr1a-deficient bone phenotype was rescued by enhancing BMPR1A signaling, with restoration of osteoclastogenesis. These findings demonstrate that BMPR1A signaling in osteoblasts restrain endogenous bone mass directly by upregulating osteoclastogenesis through the RANKL-OPG pathway, or indirectly by downregulating canonical Wnt signaling through sclerostin, a Wnt inhibitor and a bone mass mediator.

Pubmed ID: 18927151


  • Kamiya N
  • Ye L
  • Kobayashi T
  • Mochida Y
  • Yamauchi M
  • Kronenberg HM
  • Feng JQ
  • Mishina Y


Development (Cambridge, England)

Publication Data

November 27, 2008

Associated Grants

  • Agency: NIEHS NIH HHS, Id: ES071003-11
  • Agency: NIDCR NIH HHS, Id: K22 DE016977
  • Agency: NIDCR NIH HHS, Id: K22 DE016977-03
  • Agency: NIDDK NIH HHS, Id: P01 DK056246
  • Agency: NIDDK NIH HHS, Id: P01 DK056246-090001
  • Agency: NIDDK NIH HHS, Id: P01 DK56246
  • Agency: NIAMS NIH HHS, Id: R01 AR051587
  • Agency: NIAMS NIH HHS, Id: R01 AR051587
  • Agency: NIAMS NIH HHS, Id: R01 AR051587-04
  • Agency: NIAMS NIH HHS, Id: R21 AR052824
  • Agency: NIAMS NIH HHS, Id: R21 AR052824
  • Agency: NIAMS NIH HHS, Id: R21 AR052824-02
  • Agency: Intramural NIH HHS, Id: Z01 ES071003-10

Mesh Terms

  • Animals
  • Biological Markers
  • Bone Density
  • Bone Morphogenetic Protein Receptors, Type I
  • Bone Morphogenetic Proteins
  • Bone and Bones
  • Collagen Type I
  • Down-Regulation
  • Embryo, Mammalian
  • Gene Expression Regulation, Developmental
  • Genetic Markers
  • Glycoproteins
  • Integrases
  • Mice
  • Mice, Transgenic
  • Organ Size
  • Organ Specificity
  • Osteoprotegerin
  • RANK Ligand
  • Signal Transduction
  • Wnt Proteins